Apoptosis as a therapeutic tool in IBD?

Annals of the New York Academy of Sciences

Volumn 1072, Issue , 2006, Pages 62-77

  Lügering, Andreas ^a   Lebiedz, Pia ^a   Koch, Stefan ^a   Kucharzik, Torsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Anti TNF; Apoptosis; IBD; Mononuclear cells; Target

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; CYTOKINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; ONERCEPT; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CONFERENCE PAPER; CROHN DISEASE; DRUG MECHANISM; ENTERITIS; IMMUNE SYSTEM; INFLAMMATION; MONONUCLEAR CELL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN;

EID: 33748990125     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1326.013     Document Type: Conference Paper

References (81)

1. NEURATH, M.F., S. FINOTTO & L.H. GLIMCHER. 2002. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8: 567-573.
2. STROBER, W., I.J. FUSS & R.S. BLUMBERG. 2002. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20: 495-549.
3. RUGTVEIT, J. et al. 1997. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112: 1493-1505.
4. ROGLER, G. 2004. Update in inflammatory bowel disease pathogenesis. Curr. Opin. Gastroenterol. 20: 311-317.
5. BOIRIVANT, M. et al. 1999. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116: 557-565.
6. INA, K. et al. 1999. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 163: 1081-1090.
7. ATREYA, R. et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588.
8. ITOH, J. et al. 2001. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 49: 35-41.
9. STURM, A. et al. 2004. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 53: 1624-1631.
10. DOERING, J. et al. 2004. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 53: 1632-1638.
11. SCHMIDT, M. et al. 1999. Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta. J. Immunol. 163: 3484-3490.
12. SCHMIDT, M. et al. 2001. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J. Immunol. 166: 1344-1351.
13. TEN HOVE, T. et al. 2002. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50: 206-211.
14. LUGERING, A. et al. 2001. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145-1157.
15. TIEDE, I. et al. 2003. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111: 1133-1145.
16. GENESTIER, L. et al. 1998. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest. 102: 322-328.
17. CUTOLO, M. et al. 2000. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J. Rheumatol. 27: 2551-2557.
18. NAUJOKAT, C. et al. 2003. Cell cycle- and activation-dependent regulation of cyclosporin A-induced T cell apoptosis. Biochem. Biophys. Res. Commun. 310: 347-354.
19. MIGITA, K. & K. EGUCHI. 2001. FK 506-mediated T-cell apoptosis induction. Transplant. Proc. 33: 2292-2293.
20. GOCKEL, H.R. et al. 2004. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J. Immunol. 172: 5103-5109.
21. FELDMANN, M. & R.N. MAINI. 2001. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196.
22. RUTGEERTS, P., G. VAN ASSCHE & S. VERMEIRE. 2004. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610.
23. DERKX, B. et al. 1993. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 342: 173-174.
24. LOCKSLEY, R.M., N. KILLEEN & M.J. LENARDO. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
25. VARFOLOMEEV, E.E. & A. ASHKENAZI. 2004. Tumor necrosis factor: an apoptosis JuNKie? Cell 116: 491-497.
26. BREESE, E.J. et al. 1994. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466.
27. NICHOLLS, S. et al. 1993. Cytokines in stools of children with inflammatory bowel disease or infective diarrhea. J. Clin. Pathol. 46: 757-760.
28. GAMBLE, J.R. et al. 1985. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumornecrosis factor. Proc. Natl. Acad. Sci. USA 82: 8667-8671.
29. CARLOS, T.M. & J.M. HARLAN. 1994. Leukocyte-endothelial adhesion molecules. Blood 84: 2068-2101.
30. LEVI, M. et al. 1993. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 270: 975-979.
31. PLEVY, S.E. et al. 1997. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 159: 6276-6282.
32. PENDER, S.L. et al. 1998. Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology 115: 573-583.
33. BARNES, P.J. 1998. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond). 94: 557-572.
34. DIAB-ASSEF, M. et al. 2002. The phosphodiesterase inhibitor, pentoxifylline, alters rat intestinal epithelial cell proliferation via changes in the expression of transforming growth factors. Scand. J. Gastroenterol. 37: 206-214.
35. REIMUND, J.M. et al. 1997. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40: 475-480.
36. BAUDITZ, J., S. WEDEL & H. LOCHS. 2002. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200.
37. GORDON, J.N. & P.M. GOGGIN. 2003. Thalidomide and its derivatives: emerging from the wilderness. Postgrad. Med. J. 79: 127-132.
38. EHRENPREIS, E.D. et al. 1999. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117: 1271-1277.
39. VASILIAUSKAS, E. A. et al. 1999. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117: 1278-1287.
40. SAMPAIO, E.P. et al. 1991. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173: 699-703.
41. SETTLES, B. et al. 2001. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell. Mol. Biol. (Noisy-le-Grand) 47: 1105-1114.
42. HOMMES, D. et al. 2002. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122:7-14.
43. ELLIOTT, M.J. et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36: 1681-1690.
44. HANAUER, S.B. et al. 2002. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549.
45. RUTGEERTS, P. et al. 2004. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402-413.
46. RUTGEERTS, P. et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353: 2462-2476.
47. YOUDIM, A. et al. 2004. A pilot study of adalimumab in infliximab-allergic patients. Inflamm. Bowel Dis. 10: 333-338.
48. SANDBORN, W.J. et al. 2004. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. 99: 1984-1989.
49. HOCHBERG, M.C. et al. 2003. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl 2: ii13-16.
50. SANDBORN, W.J. et al. 2001. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094.
51. RUTGEERTS, P. et al. 2003. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment. Pharmacol. Ther. 17: 185-192.
52. SANDBORN, W.J. et al. 2004. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53: 1485-1493.
53. SANDBORN, W.J. et al. 2001. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330-1338.
54. SCHREIBER, S. et al. 2005. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807-818.
55. DANIAL, N.N. & S.J. KORSMEYER. 2004. Cell death: critical control points. Cell 116: 205-219.
56. POPE, R.M. 2002. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2: 527-535.
57. BAERT, F.J. et al. 1999. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 116: 22-28.
58. WAETZIG, G.H. et al. 2002. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J. Immunol. 168: 5342-5351.
59. SHEN, C. et al. 2005. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21: 251-258.
60. VAN DEN BRANDE, J.M. et al. 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774-1785.
61. DI SABATINO, A. et al. 2004. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53: 70-77.
62. MITOMA, H. et al. 2005. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128: 376-392.
63. DI SABATINO, A. et al. 2004. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment. Pharmacol. Ther. 19: 1019-1024.
64. VAN DEN BRANDE JMH, B.R., Z. DETKOVA, H. BRAAT, et al. 2004. In vivo imaging of infliximab induced apoptosis in Crohn's disease patients. Gastroenterology 126: A205.
65. SMITH, C.A., T. FARRAH & R.G. GOODWIN. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959-962.
66. WATTS, A.D. et al. 1999. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling.' EMBO J. 18: 2119-2126.
67. KIRCHNER, S. et al. 2004. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28: 67-74.
68. KIRCHNER, S. et al. 2004. LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J. Leukoc. Biol. 75: 324-331.
69. FERRAN, C. et al. 1994. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J. Clin. Invest. 93: 2189-2196.
70. DONG, C., R.J. DAVIS & R. A. FLAVELL. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20: 55-72.
71. ROSENSTIEL, P. et al. 2005. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease. Gut 54: 314-315; author reply 316-6.
72. HLAVATY T.P.M., S. JOOSSENS, G. CLAESSENS, et al. 2005. Prediction of response to infliximab in luminal and fistulizing Crohn's disease based on a decision making model using an apoptotic pharmacogenetic index and clinical predictors. Gastroenterology 128: A309.
73. WAETZIG, G.H. et al. 2005. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta 1. FASEB J. 19: 91-93.
74. FOSSATI, G. et al. 2004. Effect of the anti-TNF agents adalimumab, infliximab and certolizumab pegol on the induction of apoptosis in activated peripheral blood lymphocytes. Gastroenterology 128: A512.
75. WAETZIG, G.H. et al. 2003. Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. Gastroenterology 125: 633-634; author reply 635-636.
76. CATRINA, A.I. et al. 2005. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum. 52: 61-72.
77. EHRENSTEIN, M.R. et al. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200: 277-285.
78. BRUEWER, M. et al. 2003. Pro inflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171: 6164-6172.
79. ZEISSIG, S. et al. 2004. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 53: 1295-1302.
80. SUENAERT, P. et al. 2002. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am. J. Gastroenterol. 97: 2000-2004.
81. MARINI, M. et al. 2003. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc. Natl. Acad. Sci. USA 100: 8366-8371.